Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9047930 | 0.80 | IDO1 (0.43) | IDO1TAAR1LMNACYP2A6MEN1 | |
| SCHEMBL5506050 | 0.76 | IDO1 (0.48) | IDO1TAAR1LMNACYP2A6MEN1 | |
| SCHEMBL453913 | 0.76 | IDO1 (0.48) | IDO1TAAR1LMNACYP2A6MEN1 | |
| SCHEMBL27814917 | 0.76 | ESR1 (0.52) | IDO1TAAR1LMNAMEN1KMT2A | |
| SCHEMBL2121986 | 0.75 | IDO1 (0.42) | IDO1TAAR1LMNACYP2A6MEN1 | |
| SCHEMBL11864665 | 0.75 | IDO1 (0.42) | IDO1TAAR1LMNACYP2A6MEN1 | |
| SCHEMBL1427989 | 0.74 | ALDH1A1 (0.52) | IDO1TAAR1LMNACYP2A6MEN1 | |
| SCHEMBL2123502 | 0.74 | IDO1 (0.46) | IDO1TAAR1LMNACYP2A6AGXT | |
| SCHEMBL6083608 | 0.74 | IDO1 (0.46) | IDO1TAAR1LMNACYP2A6MEN1 | |
| SCHEMBL28879990 | 0.74 | IDO1 (0.46) | IDO1TAAR1LMNACYP2A6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111094233-B | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-03-15 | — | — | CN | claimed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | claimed |
| CN-111094233-A | Compounds, compositions and methods | 戴纳立制药公司 | 2020-05-01 | — | — | CN | claimed |
| CN-118239937-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118239938-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-111094233-B | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11851440-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20220411433-A1 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. | 2022-12-29 | — | — | US | disclosed |
| US-11236100-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | disclosed |
| CN-111094233-A | Compounds, compositions and methods | 戴纳立制药公司 | 2020-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236100-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | IDO1 4855/4885TAAR1 4870/4885LMNA 2777/4885 |
| US-11851440-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | IDO1 4855/4885TAAR1 4870/4885LMNA 2777/4885 |
| US-20220411433-A1 | Modulators of eukaryotic initiation factor 2B, compositions and methods | EIF4EBP1, EIF4B, EIF2B2 | IDO1 4855/4885TAAR1 4870/4885LMNA 2777/4885 |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | IDO1 4826/4885TAAR1 4852/4885LMNA 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.